I-SPARC: Long-Term Immune Response to mRNA COVID-19 Vaccination in 115 Cancer Patients

A prospective phase IV clinical trial by Soraia Lobo-Martins, last updated in May 2026, evaluates humoral and cellular immune responses to mRNA SARS-CoV-2 vaccination in patients with cancer. The study includes 115 patients, some receiving systemic therapy and others in remission, with longitudinal measurement of anti-Spike antibody titers and immunophenotyping of T and B cell subsets. Clinical outcomes, including SARS-CoV-2 infection, were recorded.

Use Cases

• Modeling the relationship between cancer type/treatment and anti-Spike antibody levels based on longitudinal titer measurements.
• Analyzing the effect of booster doses on immune response magnitude based on the reported significant titer increases.
• Investigating correlates of protection by linking immunophenotyping data (memory T and B cell subsets) with recorded SARS-CoV-2 infection outcomes.
• Identifying patient subgroups with the lowest vaccine response (e.g., hematologic malignancy patients) for tailored intervention strategies.

Strengths

• Data from a prospective, phase IV clinical trial (I-SPARC) with a defined cohort of 115 patients.
• Includes longitudinal measurements of anti-Spike antibodies and immunophenotyping, providing both humoral and cellular response data.
• Records clinical outcomes, with SARS-CoV-2 infection occurring in 16% of the cohort.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is 11.3 MB, indicating a relatively small scale.

Provenance

Source

Soraia Lobo-Martins via figshare.

Collection Method

Prospective phase IV clinical trial (I-SPARC).

Freshness

Last updated 2026-05-20 10:42:56.